Industry News
Biotechnology Industry News
An ‘atlas’ of the brain spurs discovery of new cells that could provide map for stroke, Alzheimer’s treatments
An 'atlas' of the brain spurs discovery of new cells that could provide map for stroke, Alzheimer's treatments klahucik Mon, 01/31/2022 - 13:23
Leo Pharma picks Christophe Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme
Leo Pharma picks Christophe Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme klahucik Mon, 01/31/2022 - 12:14
Leo Pharma picks Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme
Leo Pharma picks Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme klahucik Mon, 01/31/2022 - 12:14
Led by Nanopore and Exscientia, UK startups snag half of Europe’s biotech VC funding in record-setting 2021
Led by Nanopore and Exscientia, UK startups snag half of Europe's biotech VC funding in record-setting 2021 klahucik Mon, 01/31/2022 - 10:14
Gamida Cell readies stem cell transplant therapy for FDA submission but seeks strategic partners amid staffing cuts
Gamida Cell readies stem cell transplant therapy for FDA submission but seeks strategic partners amid staffing cuts aarmstrong Mon, 01/31/2022 - 09:33
Madrigal’s NASH prospect clears first phase 3 test, raising hopes it can magic up positive pivotal efficacy data
Madrigal's NASH prospect clears first phase 3 test, raising hopes it can magic up positive pivotal efficacy data ntaylor Mon, 01/31/2022 - 08:54
Pfizer ends $3B drug dream despite phase 2b success, leaving Regeneron with a clear run at cardiovascular market
Pfizer ends $3B drug dream despite phase 2b success, leaving Regeneron with a clear run at cardiovascular market ntaylor Mon, 01/31/2022 - 08:04
UPDATE: Kaleido confirms layoffs, halts planned phase 2 and appears to have ended COVID-19 program
UPDATE: Kaleido confirms layoffs, halts planned phase 2 and appears to have ended COVID-19 program klahucik Fri, 01/28/2022 - 14:37
Charles River Labs deals with SAMDI Tech to boost discovery business
Charles River Labs deals with SAMDI Tech to boost discovery business aarmstrong Fri, 01/28/2022 - 12:58
Yet another delay at Amryt as EMA calls in experts to inform review of rare disease drug
Yet another delay at Amryt as EMA calls in experts to inform review of rare disease drug ntaylor Fri, 01/28/2022 - 08:20
Homology scratches cash itch with manufacturing deal, bagging $130M to fund gene therapy trials
Homology scratches cash itch with manufacturing deal, bagging $130M to fund gene therapy trials ntaylor Fri, 01/28/2022 - 06:31
Taysha mulls tweaks to gene therapy trial after subject dies
Taysha mulls tweaks to gene therapy trial after subject dies ntaylor Thu, 01/27/2022 - 08:45
Neck and neck with Pfizer, Moderna gives first dose of omicron-specific booster in phase 2 trial
Neck and neck with Pfizer, Moderna gives first dose of omicron-specific booster in phase 2 trial ntaylor Thu, 01/27/2022 - 07:23
9-year J&J science chief Stoffels to steer Galapagos’ rebound as CEO
9-year J&J science chief Stoffels to steer Galapagos' rebound as CEO klahucik Wed, 01/26/2022 - 16:35
Septerna emerges with $100M to spark ‘second golden age’ of prolific drug target GPCR with pioneer as co-founder
Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with pioneer as co-founder klahucik Wed, 01/26/2022 - 15:34
Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit
Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit ntaylor Wed, 01/26/2022 - 06:49
Gilead’s $4.9B oncology bet hit with partial clinical hold, forcing pause of pivotal trials and raising doubts about CD47
Gilead's $4.9B oncology bet hit with partial clinical hold, forcing pause of pivotal trials and raising doubts about CD47 ntaylor Wed, 01/26/2022 - 05:49
Gilead tags along again to support cell therapy biotech Kyverna in $85M fundraising
Gilead tags along again to support cell therapy biotech Kyverna in $85M fundraising aarmstrong Tue, 01/25/2022 - 14:00
Pfizer, BioNTech launch trial for potential omicron-busting vaccine
Pfizer, BioNTech launch trial for potential omicron-busting vaccine aarmstrong Tue, 01/25/2022 - 09:29
Sierra’s bet on Gilead castoff pays off, teeing up FDA filing for rival to Incyte-Novartis cancer drug
Sierra's bet on Gilead castoff pays off, teeing up FDA filing for rival to Incyte-Novartis cancer drug ntaylor Tue, 01/25/2022 - 08:10